1.
Garcia-Retortillo M,
Forns X,
Feliu A,
Moitinho E,
Costa J,
Navasa M,
et al.
Hepatitis C virus kinetics during and immediately after liver transplantation.
Hepatology. 2002; 35(3) : 680
-7
[DOI][PubMed]
2.
Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation.
Gastroenterology. 2002; 122(4) : 889
-96
[PubMed]
3.
Blasco A,
Forns X,
Carrion JA,
Garcia-Pagan JC,
Gilabert R,
Rimola A,
et al.
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation.
Hepatology. 2006; 43(3) : 492
-9
[DOI][PubMed]
4.
Neumann UP,
Berg T,
Bahra M,
Seehofer D,
Langrehr JM,
Neuhaus R,
et al.
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.
J Hepatol. 2004; 41(5) : 830
-6
[DOI][PubMed]
5.
Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.
Am J Transplant. 2008; 8(3) : 679
-87
[DOI][PubMed]
6.
Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
J Hepatol. 2014; 61(1 Suppl) -31
[DOI][PubMed]
7.
Charlton M,
Gane E,
Manns MP,
Brown RJ,
Curry MP,
Kwo PY,
et al.
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Gastroenterology. 2015; 148(1) : 108
-17
[DOI][PubMed]
8.
Jensen DM,
O'Leary JG,
Pockros PJ,
Sherman KE,
Kwo PY,
Mailliard ME,
et al.
Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. 2014;
9.
Aasld Idsa Hcv Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.
Hepatology. 2015; 62(3) : 932
-54
[DOI][PubMed]
10.
Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study.
Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014;
11.
Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the RUBY-1 study.
Proceedings of the 50th Annual Meeting of the European Association for the Study of the Liver (EASL). 2015;
12.
Esmat GE, Omar RF, Khairy M, Doss W, Shiha G, Hassany M. Sofosbuvir plus ribavirin in the treatment of Egyptian patients with chronic genotype 4 HCV infection.
Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2014;
13.
Forns X,
Charlton M,
Denning J,
McHutchison JG,
Symonds WT,
Brainard D,
et al.
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Hepatology. 2015; 61(5) : 1485
-94
[DOI][PubMed]
LEAVE A COMMENT HERE: